Argos Therapeutics, Inc. Share Price

ARGSQ

US0402212023

Pharmaceuticals

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-6.22%	+78.50%

24/09/19	Argos Therapeutics, Inc. Went Out of Business	CI
24/09/19	First Amended Liquidation Plan Approved for Argos Therapeutics, Inc.	CI

Valuation: Argos Therapeutics, Inc.

Market Cap	318K 283K 262K 237K 447K 29.97M 452K 3.14M 1.23M 15.75M 1.19M 1.17M 50.2M	P/E 2016	-2.96x	P/E 2017	-0.22x
Enterprise Value	4.58M 4.09M 3.78M 3.42M 6.45M 433M 6.53M 45.35M 17.8M 227M 17.2M 16.84M 725M	EV / Sales 2016	200x	EV / Sales 2017	9.19x
Free-Float	88.73%	Yield 2016 *	-	Yield 2017	-

* Estimated data More valuation ratios

Latest news: Argos Therapeutics, Inc.

24/09/19	Argos Therapeutics, Inc. Went Out of Business	CI
24/09/19	First Amended Liquidation Plan Approved for Argos Therapeutics, Inc.	CI
30/08/19	First Amended Liquidation Plan Filed by Argos Therapeutics, Inc.	CI
21/03/19	Revised Disclosure Statement Approved on Interim Basis for Argos Therapeutics, Inc.	CI
15/03/19	Liquidation Plan and Disclosure Statement Filed by Argos Therapeutics, Inc.	CI
12/02/19	Genexine Inc. and SCM Lifescience Co. completed the acquisition of substantially all of the assets of Argos Therapeutics Inc.	CI
23/01/19	Motion for Asset Sale Approved for Argos Therapeutics, Inc.	CI
22/01/19	Notice of Successful Bidder Filed by Argos Therapeutics, Inc.	CI
21/01/19	Genexine Inc. and SCM Lifescience Co. entered into an asset purchase agreement to acquire substantially all of the assets of Argos Therapeutics Inc. for $11.3 million.	CI
21/01/19	CELLSCRIPT, LLC and Immune and Cell Therapies, LLC cancelled the acquisition of substantially all of the non-cash assets of Argos Therapeutics, Inc..	CI
20/12/18	Bidding Procedure Approved for Argos Therapeutics, Inc.	CI
06/12/18	Argos Therapeutics, Inc. will Change its Ticker to ARGSQ from ARGS	CI
03/12/18	Argos Therapeutics, Inc. Announces Management Changes	CI

More news

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Employees

Sector

Pharmaceuticals

More about the company

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

Stock Market
Stocks
ARGSQ Stock

As early as today, start finding the best investment opportunities!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGOS THERAPEUTICS, INC.	-.--%	-6.22%	-	-	567K
ELI LILLY AND COMPANY	+3.25%	+4.77%	+61.40%	+127.39%	1,133B
JOHNSON & JOHNSON	+3.40%	+4.84%	+37.63%	+75.40%	621B
ABBVIE INC.	-0.33%	+0.07%	+24.02%	+95.96%	503B
ROCHE HOLDING AG	+0.03%	+3.27%	+39.79%	+65.06%	379B
MERCK & CO., INC.	+1.53%	+4.53%	+73.23%	+46.85%	370B
NOVARTIS AG	+1.58%	+2.37%	+22.91%	+52.52%	292B
ASTRAZENECA PLC	+2.90%	+2.22%	+3.51%	+28.51%	262B
AMGEN INC.	+2.48%	+3.30%	+51.48%	+64.20%	237B
GILEAD SCIENCES, INC.	+1.33%	-1.12%	+28.12%	+100.63%	190B
Average	+1.56%	+2.27%	+38.01%	+72.95%	398.8B
Weighted average by Cap.	+2.02%	+3.73%	+43.22%	+84.91%

	2016	2017
Net sales	945K 843K 780K 706K 1.33M 89.22M 1.35M 9.35M 3.67M 46.9M 3.55M 3.47M 149M	1.9M 1.69M 1.57M 1.42M 2.67M 179M 2.7M 18.79M 7.37M 94.21M 7.13M 6.98M 300M
Net income	-53.03M -47.25M -43.75M -39.59M -74.59M -5B -75.47M -525M -206M -2.63B -199M -195M -8.38B	-40.58M -36.16M -33.48M -30.3M -57.08M -3.83B -57.75M -401M -157M -2.01B -152M -149M -6.41B
Net Debt	-13.11M -11.68M -10.81M -9.79M -18.44M -1.24B -18.66M -130M -50.88M -650M -49.17M -48.15M -2.07B	4.27M 3.8M 3.52M 3.19M 6M 403M 6.07M 42.21M 16.56M 212M 16.01M 15.67M 675M

Argos Therapeutics, Inc. Share Price

Stocks

ARGSQ

US0402212023

Pharmaceuticals

Valuation: Argos Therapeutics, Inc.

Latest news: Argos Therapeutics, Inc.

Biopharmaceuticals

Financials

Company Profile